ClavystBio

ClavystBio ClavystBio was established in 2021 by CLA Real Estate Holdings, a wholly-owned subsidiary of Temasek. Singapore's sovereign wealth fund. Since 2022, the firm has committed over $220M to biotech, diagnostics, and digital health companies, with 23 total investments including 11 direct companies and 3 early-stage VC fund positions. Focus areas include cell and gene therapy, biomarkers, digital health, and life sciences commercialization. The firm operates Node 1, a physical space in Sin